Approximately 30 million people have diabetes in the United States (US),1 the majority of which will not meet their therapeutic goals despite treatment with multiple ADs.2 Incretin‐based drugs, including glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs), are an important addition to the therapeutic options available for treatment of type 2 diabetes (T2D).3 This class of drugs is associated with a reduction in glycated haemoglobin (HbA1c), weight loss and minimal risk of hypoglycaemia.4, 5, 6, 7 A reduced risk of cardiovascular events was also seen for some drugs in this class.8, 9. This evidence concerns the gene GCG and type 2 diabetes mellitus.